Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review

Breast

Volumn 20, Issue 5, 2011, Pages 394-406

  Chirgwin, J ^a   Chua, S L ^a  

^a Maroondah Breast Clinic   (Australia)

Author keywords

130 nm albumin bound paclitaxel; Adjuvant chemotherapy; Breast neoplasms; Neoadjuvant therapy; Neoplasm metastasis; Taxane

Indexed keywords

ALBUMIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; METHOTREXATE; NANOPARTICLE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ALOPECIA; ANEMIA; ARTERY THROMBOSIS; ARTHRALGIA; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFECTION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 80052490338     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.06.004     Document Type: Review

References (66)

1. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer 2008, 8(Suppl. 2):S61-S70.
2. Stinchcombe T.E., Socinski M.A., Walko C.M., O'Neil B.H., Collichio A., Ivanova A., et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007, 60:759-766.
3. Piccart M. nab-paclitaxel: a targeted chemotherapy to improve outcomes in metastatic breast cancer. Asia Pac J Oncol Hematol 2009, 1:5-12.
4. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
5. Gradishar W.J., Krasnojon D., Cheporov S., Makhson A.N., Manikhas G.M., Clawson A., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 27:3611-3619.
6. Carrick S., Parker S., Thornton C.E., Ghersi D., Simes J., Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009, CD003372.
7. Albain K.S., Nag S.M., Calderillo-Ruiz G., Jordaan J.P., Llombart A.C., Pluzanska A., et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008, 26:3950-3957.
8. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub J.P., Cervantes G., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20:2812-2823.
9. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10:20-29.
10. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
11. Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M, et al. Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network Study, #I-04-012) (poster). Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Atlanta, USA, 30 May-3 June 2008: Abstract 1118.
12. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
13. Conlin A.K., Hudis C.A., Bach A., Moynahan M., Lake D., Forero-Torres A., et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer. J Clin Oncol 2009, 27(Suppl.):1006.
14. Danso MA, Blum JL, Robert NJ, Krekow L, Rotche R, Smith DA, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 30 May-3 June 2008: Abstract 1075.
15. Dieras V., Glaspy J., Brufsky A., Bondarkenko I., Lipatov O., Perez E.A., et al. Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Eur J Cancer Suppl 2009, 7:264. (Abstract PD-5016).
16. Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Presentation at 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, USA, 9-13 December 2009: Abstract 42.
17. Link J.S., Waisman J.R., Nguyen B., Jacobs C.I. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 2007, 7:779-783.
18. Chien A.J., Illi J.A., Ko A.H., Dubey S., Jahan T.M., Hylton N.M., et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res 2009, 15:5569-5575.
19. Abu-Khalaf MM, Gettinger SN, Trieu VN, Deshpande HA, DiGiovanna M, Azodi M, et al. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract 2534.
20. Moreno-Aspitia A., Perez E.A. N0531: phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer 2005, 6:361-364. North Central Cancer Treatment Group.
21. Roy V., LaPlant B.R., Gross G.G., Bane C.L., Palmieri F.M., Perez E.A. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009, 20:449-453. North Central Cancer Treatment Group.
22. Gudena V., Montero A.J., Glück S. Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Therapeut Clin Risk Manage 2008, 4:1157-1164.
23. Glück S, Lobo C, Lopes G, Hurley J, Reis I, Seo P, et al. Final results of a phase 2 study of the combination of nab-paclitaxel, gemcitabine, and bevacizumab as first-line therapy in patients with HER2-negative metastatic breast cancer. Presentation at 7th European Breast Cancer Conference, Barcelona, Spain, 24-27 March 2010: Abstract 470.
24. Somer B, Schwartzberg LS, Arena F, Mintzer D, Epperson A, Fu D, et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel: ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC) (poster). Presentation at 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 1-5 June 2007: Abstract 1053.
25. Burris H., Yardley D., Jones S., Houston G., Broome C., Thompson D., et al. Phase II trial of trastuzumab followed by weekly paclitaxel/ carboplatin as first line treatment for patients with metastatic breast cancer. J Clin Oncol 2004, 22:1621-1629.
26. Robert N., Leyland-Jones B., Asmar L., Belt R., Llegbodu D., Loesch D., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2006, 24:2786-2792.
27. Bullock K., Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008, 13:515-525.
28. Conlin A.K., Seidman A.D., Bach A., Lake D., Dickler M., D'Andrea G., et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010, 10:281-287.
29. Mehta RS, Kong K, Schubbert T. Weekly nab-paclitaxel (nab-T) ± carboplatin (C) ± bevacizumab (B) or ± trastuzumab (H): clinical response in patients with advanced breast cancer. Presentation at 1st American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, USA, 7-8 September 2007: Abstract 162.
30. Hamilton EP, Kimmick GG, Desai N, Singh S, Hopkins JO, Marcom PK, et al. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract 1109.
31. Blackwell KL, Hamilton EP, Rocha G, Gainey M, Trieu VN, Motamed K, et al. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract e21040.
32. Yardley D.A., Zubkus J., Daniel B., Lahiry A., LoCicero R., Thompson D., et al. A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clin Breast Cancer 2010, 10:E16-E21.
33. Paz IB, Lau S, Garberoglio C, Luu TH, Chung CT, Mortimer J, et al. nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC). Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 30 May-3 June 2008: Abstract 567.
34. Mehta RS. In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) → weekly carboplatin and albumin-bound paclitaxel (nab-TC) plus trastuzumab (H) or bevacizumab (B) in patients with large and inflammatory breast cancer (BC): a phase II study. Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 30 May-3 June 2008: Abstract 11569.
35. Robidoux A., Buzdar A.U., Quinaux E., Jacobs S., Rastogi P., Fourchotte V., et al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010, 10:81-86.
36. Sachdev JC, Kronish LE, West S, Schwartzberg L, Jahanzeb M, University of Tennessee Cancer Institute, Memphis, TN, et al. Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract TPS100.
37. Inhorn RC, Daniel B, Daniel D, Naot Y, Zubkus J, Lane C, et al. Neoadjuvant gemcitabine, epirubicin, and nab-paclitaxel (GEA) in patients with localized breast cancer: correlation of treatment efficacy with tumor expression of SPARC (poster). Presentation at 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, USA, 29 May-2 June 2009: Abstract 618.
38. Veerapaneni A, Boisvert M, Choi A, Aggarwal A. Capecitabine and ABI-007 chemotherapy as neoadjuvant treatment of locally advanced breast cancer. Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 30 May-3 June 2008: Abstract 11535.
39. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
40. Kaklamani V., Uthe R., Khan S., Hansen N., Bethke K., Jeruss J., et al. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat 2011 Feb 27, [Epub ahead of print].
41. Zelnak AB, Leyland-Jones B, Gabram-Mendola S, Styblo TM, Rizzo M, Wood WC, et al. High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy. Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract 625.
42. Somlo G, Frankel PH, Vora L, Lau S, Luu TH, Kruper L, et al. Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin ± trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC). Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract 540.
43. Rizack T, Abu-Khalaf MM, Legare RD, Strenger R, Fenton MA, Sakr BJ, et al. Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: interim dose delivery and toxicity data. Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract e11010.
44. Mrozek E, Lustberg MB, Knopp MV, Spigos DG, Yang X, Houton LA, et al. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract 604.
45. Raefsky E, Castillo R, Lahiry A, Thompson DS, Hanson S, Meng C, et al. Phase II study of neoadjuvant bevacizumab and trastuzumab administered with nano-particle albumin bound paclitaxel (nab paclitaxel) and carboplatin in HER2 overexpressing locally advanced breast cancer (poster). Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 30 May-3 June 2008: Abstract 627.
46. Yardley DA, Raefsky E, Castillo R, Lahiry A, LoCicero R, Thompson D, et al. Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. Presentation at 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, USA, 29 May-2 June 2009: Abstract 527.
47. Tang S.-C. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions. Cancer Invest 2009, 27:489-495.
48. von Minckwitz G, on behalf of the German Breast Group. ICE II: an investigational randomized phase II study on epirubicin (E) plus cyclophosphamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast. Presentation at 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 2010: Abstract TPS104.
49. Pippen J., Paul D., Richards D., Bhar P., Iglesias J. Dose-dense nab-paclitaxel vs paclitaxel with bevacizumab following adriamycin and cytoxan is safe as adjuvant therapy in patients with early-stage breast cancer. Breast 2009, 18(Suppl. 1):S57. (Abstract 0152).
50. McArthur HL, Rugo H, Nulsen B, Patil S, Steingart R, Melisko M, et al. Troponins do not predict cardiotoxicity in a pilot study of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P). Presentation at 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, USA, 9-13 December 2009: Abstract 3087.
51. McArthur HL, Rugo H, Paulson M, Rourke M, Traina T, Panageas K, et al. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Presentation at 30th Annual San Antonio Breast Cancer Symposium, San Antonio, USA, 13-16 December 2007: Abstract 3065.
52. Sierecki MR, Rugo HS, McArthur HL, Traina TA, Paulson M, Rourke M, et al. Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC). Presentation at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA, 30 May-3 June 2008: Abstract 589.
53. Force R.W., Brooke A.P., Culbertson V.L. Comparing medical costs of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis. Am Health Drug Benefits 2010, 3:276-284.
54. Dranitsaris G., Coleman R., Gradishar W. nab-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomised trial. Breast Cancer Res Treat 2010, 119:717-724.
55. Dranitsaris G., Cottrell W., Sprirovski B., Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 2009, 15:67-78.
56. Wildiers H., Neven P., Christiaens M.R., Squifflet P., Amant F., Weltens C., et al. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. J Clin Oncol 2007 Apr 1, 25(10):1232-1238. Epub 2007 Feb 12.
57. Limentani S.A., Brufsky A.M., Erban J.K., Jahanzeb M., Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2005 Jul 1, 23(19):4265-4274. Epub 2005 May 23.
58. Marty M., Cognetti F., Maracninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
59. Valero V., Forbes J., Pegram M.D., Pienkowski T., Eiermann W., Von Minckwitz G., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011, 29:149-156.
60. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
61. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-Negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
62. Brufsky A., Bonarenko I., Smirnov V., Hurvitz S., Perez E., Ponomarova O., et al. RIBBON-2: a randomized, double-blind, placebo controlled, phase III trail evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009, 69(24 Suppl.). Abstract nr 42.
63. Seidman A.D., Brufsky A., Ansari R.H., Rubinsak J.R., Stein R.S., Schwartzberg L.S., et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol 2010, 22:1094-1101.
64. Sanchez-Munoz A., Duenas-Garcia R., Jaen-Morago J., Carrasco E., Chacon I., Garcia-Tapiador A.M., et al. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/ sequential combination?. Am J Clin Oncol 2010, 33:432-437.
65. Estevez L.G., Sanchez-Rovira P., Domine M., Leon A., Calvo I., Jaen A., et al. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study. Clin Transl Oncol 2007, 9:317-322.
66. Hamm J.T., Wilson J.W., Rastogi P., Lembersky B.C., Tseng G., Song Y.K., et al. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 2008, 8(3):257-263.